Search Results
Jun 05, 2026, 08:53 ET Neuronoff Implants First Patient in DOD-Funded Trial of Injectrode® for Neurogenic Bladder in Spinal Cord Injury
($1,730,406), through the (Spinal Cord Injury Research Program (SCIRP) Clinical Translation Research Award - Early-Career Partnership Option under Award No. (HT942524). Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.Contact:
More news about: Neuronoff
Jun 04, 2026, 10:01 ET Generalized Anxiety Disorder Market Forecast Shows Strong CAGR During the Forecast Period (2026-2036) Driven by Innovative Therapies | DelveInsight
reduce GAD symptoms by targeting underlying network dysregulation.Sumitomo Pharma/Otsuka's Ulotaront is an investigational TAAR1 and 5-HT1A receptor agonist being developed as a new oral therapy for GAD. By engaging these receptors, it seeks to influence neurotransmission in a manner distinct
More news about: DelveInsight Business Research, LLP
Jun 04, 2026, 06:01 ET Shipt Kits: Announcing the Game-Day MVP for One-Click Cart Building and Stress-Free Entertaining
Shopper,' real-time order updates, and more. For more information, please visit Shipt's Newsroom.*Offer valid 5/31/26 through 7/5/26 at 11:59 p.m. HT. Annual membership will renew at the standard membership rate at the end of first year. Cancellation available free of charge anytime. Offer will automatically
More news about: Shipt
Jun 03, 2026, 08:22 ET ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.) TO SPACE AND DEFENSE ADVISORY BOARD
pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly owned subsidiary.Forward-Looking Statements This
More news about: Rocket One Inc.
Jun 02, 2026, 09:29 ET Blend Acquires In516ht, a Snowflake Elite Partner, Expanding Enterprise AI Capabilities Globally
private equity, retail, manufacturing, and energy.In516ht is a Snowflake Elite Partner and was named 2025 EMEA Data Cloud Service Growth Partner of the Year. With additional recognition and competencies across the Snowflake ecosystem, In516ht is widely regarded as one of the most accomplished "True-Blue"
More news about: Blend360
Jun 02, 2026, 09:19 ET Blend Acquires In516ht, a Snowflake Elite Partner, Expanding Enterprise AI Capabilities Globally
private equity, retail, manufacturing, and energy.In516ht is a Snowflake Elite Partner and was named 2025 EMEA Data Cloud Service Growth Partner of the Year. With additional recognition and competencies across the Snowflake ecosystem, In516ht is widely regarded as one of the most accomplished "True-Blue"
More news about: Blend360
Jun 01, 2026, 10:18 ET Rocket One Appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology
pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly owned subsidiary.Forward-Looking StatementsThis
More news about: Rocket One Inc.
Jun 01, 2026, 03:04 ET China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
anaesthesia: A multicentre, single-blind, randomised, parallel-group, phase 3 clinical trial. Eur J Anaesthesiol. 2023;6.8(IF).Ding YY, Long YQ, Yang HT, et al. Efficacy and safety of ciprofol for general anaesthesia induction in elderly patients undergoing major noncardiac surgery: A randomised controlled
More news about: Haisco
Jun 01, 2026, 00:05 ET HONEYWELL UNVEILS NEW BRANDS EFFECTIVE POST SPIN-OFF: HONEYWELL TECHNOLOGIES AND HONEYWELL AEROSPACE
ambition. High-energy and kinetic, it retains the iconic Honeywell red as its anchor, alongside an expanded, more vibrant color palette and a modern "HT" monogram. The visual system, built around the concept of "intersections," reflects where the company's expertise meets technology to unlock precision,
More news about: Honeywell
May 29, 2026, 11:40 ET Le Groupe Menarini présente de nouvelles données de l'étude ELEVATE sur l'association de l'élacestrant et du capivasertib
outre, plusieurs autres points de la situation d'essais en cours seront présentés, soulignant le potentiel de l'élacestrant en tant qu'hormonothérapie (HT) de base dans l'ensemble du spectre du cancer du sein. Ces données seront présentées lors de la réunion annuelle 2026 de l'American Society of Clinical
More news about: Menarini Industrie Farmaceutiche Riunite
May 28, 2026, 08:19 ET Rocket One Accepted into AMD AI Developer Program to Advance Simulation of Next-Generation Nanomagnetic AI Accelerator Architecture for AI, Defense and Space Applications
pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly owned subsidiary.Forward-Looking Statements This
More news about: Rocket One Inc.
May 28, 2026, 08:15 ET Halia Therapeutics to Participate in Jefferies 2026 Global Healthcare Conference
pipeline of first-in-class programs, including HT-6184 in lower-risk myelodysplastic syndromes and additional hematologic indications, HT-4253 for Alzheimer's disease in APOE4 carriers, HT-6105 targeting residual inflammatory risk via hsCRP reduction, and HT-10068 for metabolic disease. To learn more, visit
More news about: Halia Therapeutics
May 27, 2026, 08:11 ET Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications
pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly owned subsidiary.Forward-Looking
More news about: Hoth Therapeutics, Inc.
May 26, 2026, 08:30 ET From smart agriculture to mental health: These are the New U.S.-Israel projects set to receive $7.5 million from the BIRD Foundation
Israel) and Nutrien Ag Solutions (Loveland, CO) to develop and validate an AI-driven targeted spraying system for agricultural retailersHT Vet (Hod Hasharon, Israel) and VCA Animal Hospitals (Los Angeles, CA) to develop non-invasive skin and subcutaneous tumor screening for cats
More news about: The BIRD Foundation
May 26, 2026, 08:18 ET Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform
mast cell platform and an important addition to the intellectual property foundation supporting HT-KIT," said Robb Knie, Chief Executive Officer of Hoth Therapeutics.About HT-KITHT-KIT is Hoth Therapeutics' orphan drug–designated program directed at mastocytosis and other mast
More news about: Hoth Therapeutics, Inc.
May 19, 2026, 08:15 ET Halia Therapeutics Appoints Gary Sabin as Executive Chairman and Adds Three Independent Directors to Board
pipeline of first-in-class programs, including HT-6184 in lower-risk myelodysplastic syndromes and additional hematologic indications, HT-4253 for Alzheimer's disease in APOE4 carriers, HT-6105 targeting residual inflammatory risk via hsCRP reduction, and HT-10068 for metabolic disease. To learn more, visit
More news about: Halia Therapeutics
May 18, 2026, 08:07 ET KUMHO TIRE U.S.A. ANNOUNCES ROAD VENTURE HT HIGHWAY-TERRAIN TIRE
leading tire manufacturers, today announced the all-new Road Venture HT, an advanced all-season Highway-Terrain tire engineered for optimal performance across any road condition. Developed with innovative technology, the Road Venture HT is purpose-built for light truck and SUV owners seeking a dependable
More news about: Kumho Tire USA
May 12, 2026, 08:03 ET Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
MDSDr. Myint, a hematology leader and oncology drug-development executive, joins Halia to lead clinical development as ofirnoflast (HT-6184) advances toward pivotal trialsLEHI, Utah, May 12, 2026 /PRNewswire/
More news about: Halia Therapeutics
May 11, 2026, 08:00 ET Coalition for Health AI (CHAI) Releases Best Practice Guides for Responsible AI in Medicaid Eligibility
HealthTech 4 Medicaid (HT4M)HealthTech for Medicaid (HT4M) is a national nonprofit and mission-driven market enabler that advances innovation in Medicaid by fostering cross-sector collaboration. Through program development, ecosystem building, and policy and advocacy efforts, HT4M brings together
More news about: Coalition for Health AI
May 11, 2026, 08:00 ET Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
CAPLYTA® is unknown, the efficacy of CAPLYTA® could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors.About SeltorexantSeltorexant, an investigational
More news about: Johnson & Johnson
May 05, 2026, 16:17 ET Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
Reactions) is a Phase 2a randomized, placebo-controlled, parallel, dose-ranging study evaluating HT-001 in patients experiencing EGFR inhibitor-related dermatologic toxicities.About HT-001HT-001 is a novel topical therapeutic designed to target inflammatory pathways associated with
More news about: Hoth Therapeutics, Inc.
May 04, 2026, 16:05 ET MATSON, INC. ANNOUNCES FIRST QUARTER 2026 RESULTS
Time:4:30 p.m. ET / 1:30 p.m. PT / 10:30 a.m. HTThe conference call will be broadcast live along with an additional slide presentation on the Company's website at
More news about: Matson, Inc.
May 04, 2026, 08:00 ET CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
CAPLYTA® is unknown, the efficacy of CAPLYTA® could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors.A supplemental New Drug Application (sNDA) for CAPLYTA®
More news about: Johnson & Johnson
Apr 30, 2026, 09:00 ET Theradaptive Secures FDA Approval to Advance OASIS Trial to Pivotal Study Evaluating OsteoAdapt® SP in Spinal Fusion
Assistant Secretary of Defense for Health Affairs in the Department of Defense, through the Peer Reviewed Medical Research Program under Award No. HT9425-23-1-0693. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary
More news about: Theradaptive
Apr 29, 2026, 12:14 ET Immune Cells Rewire Themselves to Keep Battling Tumors in Nutrient Poor Environments
Investigator Award (WB), Ludwig Institute for Cancer Research (WB), NIH grant P30CA016520 (CSC), NIH grant R35GM154896 (CSC), Department of Defense grant HT9425- 23-1-0082 (CSC), NIH grant F31CA261156 (LT), and NIH T32CA009140 (KR)Scaglione et al. "Metabolic and transcriptional plasticity supports
More news about: Children's Hospital of Philadelphia